Night shift work has been consistently associated with higher risk for cardiovascular disease (CVD) and cancer. In 2007 the World Health Organization classified night shift work as a probable carcinogen due to circadian disruption. ...
Jan 5, 2015
6
2435
A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity, according to a paper published in the peer-reviewed journal Cell ...
Aug 3, 2022
0
1399
As key players in the immune system, T cells provide tumor surveillance and have direct antitumor effects. However, tumors can escape T-cell attack through various mechanisms in the tumor microenvironment. Reactivating the ...
Mar 16, 2016
0
68
Immunotherapies have greatly improved the outcomes of many patients with melanoma. But there is still a need for new approaches for the subset of patients who do not respond well to this type of therapy. Moffitt Cancer Center ...
Mar 27, 2023
0
57
Researchers have found that a synthetic version of hypericin, a compound naturally found in St. John's wort, may be a promising treatment for patients with recurrent malignant brain tumors. Their findings were published online ...
Apr 11, 2011
0
0
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...
Oct 20, 2013
0
0
Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with advanced cancers that had ...
Dec 20, 2013
0
0
In patients with metastatic triple-negative breast cancer—a disease with no approved targeted therapies—infusion of pembrolizumab produced durable responses in almost one out of five patients enrolled in a phase-Ib clinical ...
Dec 10, 2014
0
0
A better understanding of the role secreted inflammatory cytokines play in the tumor microenvironment that results in the differentiation of effector T cells into exhausted T cells points to possible approaches to improve ...
Aug 3, 2018
0
0
A new research paper titled "MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway" has been published in Oncotarget.
Nov 10, 2022
0
2
